Key facts
- It has raised $102.5M; the latest was Early Stage VC ($73.0M) in Nov 2024.
- Notable investors include Index Ventures, IVP, IPV Capital, Mehdi Ghissassi, John Zimmer — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Cradle (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Cradle (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cradle (Biotechnology)
Developer of an algorithm and artificial intelligence tool designed to help scientists engineer proteins more efficiently. The company offers generative machine learning models that allow researchers to train models specific to their experimental data and generate novel protein sequences, enabling scientists to optimize protein properties faster and more accurately.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2021
- Employees
- 70
- Website
- cradle.bio/
- Ownership
- Privately Held (backing)
Cradle (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cradle (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cradle (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.